NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO – Get Free Report)’s share price rose 1.7% on Tuesday . The stock traded as high as $0.66 and last traded at $0.65. Approximately 85,989 shares were traded during trading, an increase of 117% from the average daily volume of 39,605 shares. The stock had previously closed at $0.64.
NeuroBo Pharmaceuticals Trading Up 1.7%
The company has a fifty day moving average price of $0.67 and a two-hundred day moving average price of $1.03.
About NeuroBo Pharmaceuticals
NeuroBo Pharmaceuticals, Inc, a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity.
Further Reading
- Five stocks we like better than NeuroBo Pharmaceuticals
- The Basics of Support and Resistance
- Buffett’s Cash Hoard Signals Market Caution, Value Plays Emerge
- Best Aerospace Stocks Investing
- DLocal Stock Soars 43% After Earnings Beat and Raised Guidance
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Can AI Defense Contracts Push Palantir Shares Higher?
Receive News & Ratings for NeuroBo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroBo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
